For immediate release |
4 February 2014 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Notification of Preliminary Results
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its preliminary results for the year ended 31 December 2013 on Wednesday 26 March 2014.
A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
For more information, or to register attendance, please contact Buchanan on 020 7466 5000.
For further information:
Alliance Pharma plc |
+ 44 (0) 1249 466966 |
|
John Dawson, Chief Executive |
|
|
Richard Wright, Finance Director |
|
|
|
|
|
Buchanan |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Fiona Henson / Sophie Cowles |
|
|
|
|
|
Numis Securities Limited |
+ 44 (0) 20 7260 1000 |
|
Nominated Adviser: Michael Meade / Oliver Cardigan / Freddie Barnfield |
|
|
Corporate Broking: David Poutney |
|
|
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.